Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline

Background: A new, effective anti-tuberculosis (TB) regimen containing bedaquiline (BDQ) and pyrifazimine (TBI-166) has been recommended for a phase IIb clinical trial. Preclinical drug–drug interaction (DDI) studies of the combination of BDQ and TBI-166 have been designed to support future clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yangming, Liu, Haiting, Wang, Furun, Fu, Lei, Zhu, Hui, Fu, Shuang, Wang, Ning, Zhuang, Xiaomei, Lu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582325/
https://www.ncbi.nlm.nih.gov/pubmed/37860115
http://dx.doi.org/10.3389/fphar.2023.1154780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582325/
https://www.ncbi.nlm.nih.gov/pubmed/37860115
http://dx.doi.org/10.3389/fphar.2023.1154780

Ejemplares similares